(GHLV, AMRN, ORFG, INVE) PennyOmega.com Stocks in Action
Global Health Ventures Inc., GHLV.OB recently completed the final formulation of X-Excite for the upcoming clinical trials in the United States.
GHLV is a specialty pharmaceutical company with expertise in drug delivery and formulation. GHLV has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route.
Sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down.
It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.
GHLV's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe.
GHLV recently completed the final formulation of X-Excite for the upcoming clinical trials in the United States.
Results of the interim clinical trials in Europe showed GHLV's X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra(R). It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption.
For North American trials, GHLV has modified the formulation slightly to give the maximal buccal absorption.
More about GHLV at www.globalhealth3000.com
***********************
ORFG, Orofino Gold Corp., ORFG.PK
ORFG is a Colombian based gold producer.
Colombia is recognized as one of the most prospective, yet under-explored countries in the world, and provides an attractive blend of gold, copper and silver deposit discovery potential within a pro-mining business atmosphere.
ORFG has several viable Gold development properties in Colombia, a current hot spot of gold production in the world markets.
ORFG's corporate objective is to continue to build shareholder value through the exploration and development of The Senderos de Oro Gold Camp and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years.
** Additional Laboratory Test Results of Culo Alzado Rock Samples **
ORFG reported results from random chip samples within their Culo Alzado mining area, on the north margin of Senderos de Oro, in Colombia that indicate high grades.
A newly recognized gold and silver zone has been discovered in this mining area and the current exploration program will be escalated as recommended by the company's Qualified Person. A complete listing of Acme Analytical Laboratories reports is available on the Company's website
Highlights
* Random chip samples returned high grades to 31.80 grams of gold per tonne in average by adopting fusion method (G6Gr).
* Random chip samples returned grades to 66.80 grams of silver per tonne in average by adopting aqua regia digestion method (7AR).
The best results generated 52.20 grams of gold per tonne (or 1.68 troy ounces of gold per tonne) and 178 grams of silver per tonne (or 5.72 troy ounces of silver per tonne).
ORFG will carry out more chip samples and begin larger scale trenching near the producing mines in the near future.
ORFG is confident that diamond drilling at the Culo Alzado area will intercept better than average grades of gold and silver mineralization and will confirm continuity of the mineralized system to depth.
** Additional Laboratory Test Results of La Azul Rock Samples **
ORFG recently reported results from random chip samples from within their La Azul mining area in Colombia that indicate very high grades. A complete listing of Acme Analytical Laboratories reports is available on the Company's website
Highlights
* Random chip samples returned high grades to 40.20 grams of gold per tonne in average (or 1.29 troy ounces per tonne) by adopting fusion method (G6Gr).
* Random chip samples returned grades to 107.40 grams of silver per tonne in average (adopting aqua regia digestion method - 7AR).
The best results generated 63.30 grams of gold per tonne (or two troy ounces of gold per tonne) and 202 grams of silver per tonne (or six and a half troy ounces of silver per tonne).
ORFG will carry-out more chip samples and begin larger scale trenching near the producing mines on the company's 9076 acres of tenure.
More about ORFG at www.orofinogoldcorp.com.
*********************
INVE, Identive Group, Inc.
INVE is a leading provider of products, services and solutions for the security, identification and RFID industries.
INVE's business unit, SCM Microsystems, is a leading provider of solutions for secure access, secure identity and secure exchange. The company offers the world's broadest range of contact, contactless and mobile smart card reader and terminal technology, digital identity and transaction platforms, as well as systems that integrate physical and logical access control. SCM's smart card-based products and solutions are utilized around the world to enable security and identification applications, transaction systems, eHealth- and eGovernment programs and physical access systems.
INVE's SCM Microsystems reported that it has received its first orders for 10,000 eHealth terminals to support the relaunch of the electronic health card program in Germany. SCM has begun shipping both its eHealth200 desktop and eHealth500 mobile health card terminals for the program, which involves the deployment of more than 80 million electronic health insurance cards to German citizens.
The German eHealth card program began in 2009, and after being suspended in 2010, was relaunched in April 2011. To encourage participation in the program, the German health insurance industry is subsidizing the purchase and installation of eHealth terminals for doctors and other healthcare professionals who order the devices between April 1 and September 30, 2011. SCM's eHealth readers are certified by the German healthcare oversight organization (gematik) and the Federal Office for Information Security (BSI) as meeting the strict security and performance requirements of the eHealth program.
More about INVE at www.identive-group.com
***********************
AMRN, Amarin Corporation plc
AMRN, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for AMRN's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
- Triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively
- LDL-C decreased at both doses within the predefined non-inferiority boundary with a statistically significant 6.2% decrease in LDL-C from baseline versus placebo at 4 gram dose
- All results were incremental to background statin therapy
- Safety profile similar to placebo and similar to MARINE trial results
- Results position AMR101 to be first-in-class product for treatment of high triglycerides
More about AMRN at at www.amarincorp.com.
**************************************************************
********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising
###
Categories: Finance
Press Release Options
Printer FriendlyAbout This Press Release
If you have any questions about this press release, please contact the listed publisher. Please do not contact prHWY as we cannot help you with your inquiry.